Pfizer and BioNTech announced the first interim analysis from the Phase III study of its COVID-19 vaccine candidate, which was found to be >90% effective in preventing COVID-19. While the results are very promising, we believe there was a large over-reaction in the market in response to the news. It should not have been unexpected – we hoped for positive results from vaccine manufacturers this month, and we hope there is more to come, as AstraZeneca-Oxford University and Moderna are also due to ....
10 Nov 2020
Rude Health - finnCap Life Sciences quarterly sector note
Cambridge Nutritional Sciences PLC (CNSL:LON), 3.4 | Synairgen plc (SNG:LON), 5.1 | Genedrive Plc (GDR:LON), 3.4 | hVIVO plc (HVO:LON), 29.0
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Rude Health - finnCap Life Sciences quarterly sector note
Cambridge Nutritional Sciences PLC (CNSL:LON), 3.4 | Synairgen plc (SNG:LON), 5.1 | Genedrive Plc (GDR:LON), 3.4 | hVIVO plc (HVO:LON), 29.0
- Published:
10 Nov 2020 -
Author:
Mark Brewer | Cavendish Research -
Pages:
4
Pfizer and BioNTech announced the first interim analysis from the Phase III study of its COVID-19 vaccine candidate, which was found to be >90% effective in preventing COVID-19. While the results are very promising, we believe there was a large over-reaction in the market in response to the news. It should not have been unexpected – we hoped for positive results from vaccine manufacturers this month, and we hope there is more to come, as AstraZeneca-Oxford University and Moderna are also due to ....